Medical treatment of neuroendocrine neoplasms

Wouter W. de Herder*, Richard A. Feelders, Johannes Hofland

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

4 Downloads (Pure)

Abstract

Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalCurrent Opinion in Endocrine and Metabolic Research
Volume18
DOIs
Publication statusPublished - Jun 2021

Bibliographical note

Funding Information:
WWH received speaker fees from Novartis – AAA, Ipsen and Pfizer and research support from Ipsen .

Publisher Copyright:
© 2021

Fingerprint

Dive into the research topics of 'Medical treatment of neuroendocrine neoplasms'. Together they form a unique fingerprint.

Cite this